Safety, Ultrasound Conspicuity, and Migration of Twinkling Markers in Patients With Locally Advanced Breast Cancer
A Phase 1 Study in Patients With Clinically Node-Positive Breast Cancer to Assess the Safety, Ultrasound Conspicuity, and Migration of an Ultrasound Twinkling Marker Obeservedfor Sonographic Targeting (UTMOST TRIAL)
Sponsor: Mayo Clinic
Suspended
Pending biocompatibility testing
Listed as NCT05547347, this observational or N/A phase trial focuses on Anatomic Stage III Breast Cancer AJCC v8 and Locally Advanced Breast Carcinoma and remains suspended. Sponsored by Mayo Clinic, it has been updated 13 times since 2023, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Nov 2025 — Present [monthly]
Suspended
Status: Enrolling By Invitation → Suspended
-
Jun 2025 — Nov 2025 [monthly]
Enrolling By Invitation
-
Apr 2025 — Jun 2025 [monthly]
Enrolling By Invitation
-
Mar 2025 — Apr 2025 [monthly]
Enrolling By Invitation
-
Oct 2024 — Mar 2025 [monthly]
Enrolling By Invitation
▶ Show 8 earlier versions
-
Sep 2024 — Oct 2024 [monthly]
Enrolling By Invitation
-
Jul 2024 — Sep 2024 [monthly]
Enrolling By Invitation
-
Nov 2023 — Jul 2024 [monthly]
Enrolling By Invitation
-
Aug 2023 — Nov 2023 [monthly]
Enrolling By Invitation
Status: Not Yet Recruiting → Enrolling By Invitation
-
May 2023 — Aug 2023 [monthly]
Not Yet Recruiting
-
Feb 2023 — May 2023 [monthly]
Not Yet Recruiting
-
Nov 2022 — Feb 2023 [monthly]
Not Yet Recruiting
-
Sep 2022 — Nov 2022 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Mayo Clinic
For direct contact, visit the study record on ClinicalTrials.gov .